WO2002066040A3 - Sensibilisation des cellules neoplasiques resistant aux agents chimiotherapeutiques avec un reovirus - Google Patents

Sensibilisation des cellules neoplasiques resistant aux agents chimiotherapeutiques avec un reovirus Download PDF

Info

Publication number
WO2002066040A3
WO2002066040A3 PCT/CA2002/000201 CA0200201W WO02066040A3 WO 2002066040 A3 WO2002066040 A3 WO 2002066040A3 CA 0200201 W CA0200201 W CA 0200201W WO 02066040 A3 WO02066040 A3 WO 02066040A3
Authority
WO
WIPO (PCT)
Prior art keywords
reovirus
neoplastic cells
sensitization
chemotherapeutic agent
agent resistant
Prior art date
Application number
PCT/CA2002/000201
Other languages
English (en)
Other versions
WO2002066040A8 (fr
WO2002066040A2 (fr
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Matthew C Coffey
Bradley G Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0207691-8A priority Critical patent/BR0207691A/pt
Priority to JP2002565598A priority patent/JP4951194B2/ja
Application filed by Oncolytics Biotech Inc, Matthew C Coffey, Bradley G Thompson filed Critical Oncolytics Biotech Inc
Priority to EP02701122A priority patent/EP1361884B1/fr
Priority to DK02701122.0T priority patent/DK1361884T3/da
Priority to IL15716702A priority patent/IL157167A0/xx
Priority to AU2002234453A priority patent/AU2002234453B2/en
Priority to CA002437468A priority patent/CA2437468C/fr
Priority to MXPA03007486A priority patent/MXPA03007486A/es
Priority to AT02701122T priority patent/ATE516807T1/de
Priority to NZ527399A priority patent/NZ527399A/en
Publication of WO2002066040A2 publication Critical patent/WO2002066040A2/fr
Publication of WO2002066040A8 publication Critical patent/WO2002066040A8/fr
Publication of WO2002066040A3 publication Critical patent/WO2002066040A3/fr
Priority to IL157167A priority patent/IL157167A/en
Priority to HK04103556.6A priority patent/HK1060520A1/xx
Priority to AU2007207860A priority patent/AU2007207860B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé pour augmenter la sensibilité des cellules néoplasiques résistant aux agents chimiothérapeutiques avec un réovirus, un procédé pour traiter les troubles prolifératifs avec un réovirus et des agents chimiothérapeutiques, de même qu'un procédé pour empêcher un néoplasme de développer une résistance aux agents chimiothérapeutiques.
PCT/CA2002/000201 2001-02-20 2002-02-19 Sensibilisation des cellules neoplasiques resistant aux agents chimiotherapeutiques avec un reovirus WO2002066040A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AT02701122T ATE516807T1 (de) 2001-02-20 2002-02-19 Sensibilisierung von für chemotherapeutische mittel resistenten neoplastischen zellen durch reoviren
MXPA03007486A MXPA03007486A (es) 2001-02-20 2002-02-19 Sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus.
EP02701122A EP1361884B1 (fr) 2001-02-20 2002-02-19 Sensibilisation des cellules neoplasiques resistant aux agents chimiotherapeutiques avec un reovirus
JP2002565598A JP4951194B2 (ja) 2001-02-20 2002-02-19 レオウイルスを用いる化学療法薬剤耐性新生物細胞の感作
IL15716702A IL157167A0 (en) 2001-02-20 2002-02-19 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
AU2002234453A AU2002234453B2 (en) 2001-02-20 2002-02-19 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
NZ527399A NZ527399A (en) 2001-02-20 2002-02-19 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
BR0207691-8A BR0207691A (pt) 2001-02-20 2002-02-19 Método para tornar uma célula neoplástica sensìvel a um agente quimioterápico, método para tratar um sujeito que abrigue um distúrbio proliferativo, método para impedir que um neoplasma em um sujeito desenvolva resistência a um agente quimioterápico, e, método para tratar um sujeito com um agente quimioterápico
DK02701122.0T DK1361884T3 (da) 2001-02-20 2002-02-19 Sensibilisering af neoplastiske celler, der er resistente over for kemoterapeutisk middel, med reovirus
CA002437468A CA2437468C (fr) 2001-02-20 2002-02-19 Sensibilisation des cellules neoplasiques resistant aux agents chimiotherapeutiques avec un reovirus
IL157167A IL157167A (en) 2001-02-20 2003-07-30 Reovirus medicinal product and antitumor for the treatment or prevention of cancer and commercial packaging containing the reovirus and antitumor
HK04103556.6A HK1060520A1 (en) 2001-02-20 2004-05-19 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
AU2007207860A AU2007207860B2 (en) 2001-02-20 2007-08-16 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with Reovirus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27036301P 2001-02-20 2001-02-20
US60/270,363 2001-02-20

Publications (3)

Publication Number Publication Date
WO2002066040A2 WO2002066040A2 (fr) 2002-08-29
WO2002066040A8 WO2002066040A8 (fr) 2003-03-20
WO2002066040A3 true WO2002066040A3 (fr) 2003-05-30

Family

ID=23031034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000201 WO2002066040A2 (fr) 2001-02-20 2002-02-19 Sensibilisation des cellules neoplasiques resistant aux agents chimiotherapeutiques avec un reovirus

Country Status (16)

Country Link
US (5) US7264798B2 (fr)
EP (2) EP2314301A3 (fr)
JP (3) JP4951194B2 (fr)
AR (1) AR035227A1 (fr)
AT (1) ATE516807T1 (fr)
AU (2) AU2002234453B2 (fr)
BR (1) BR0207691A (fr)
CA (1) CA2437468C (fr)
DK (1) DK1361884T3 (fr)
ES (1) ES2367768T3 (fr)
HK (1) HK1060520A1 (fr)
IL (2) IL157167A0 (fr)
MX (1) MXPA03007486A (fr)
NZ (2) NZ527399A (fr)
WO (1) WO2002066040A2 (fr)
ZA (1) ZA200305875B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
DK1505993T3 (da) * 2002-05-10 2012-05-21 Oncolytics Biotech Inc Sensibilisering af neoplastiske celler for stråleterapi med onkolytiske vira
EP1617722A2 (fr) * 2003-04-25 2006-01-25 Wellstat Biologics Corporation Utilisation de virus therapeutiques pour le traitement des carcinomes hepatocellulaires
ATE420160T1 (de) 2003-06-18 2009-01-15 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
JP5170741B2 (ja) * 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
WO2005112966A1 (fr) * 2004-05-21 2005-12-01 Orison Biotechnology Inc. Thérapie combinée extrait végétal plus un réovirus pour tuer les cellules néoplasiques chez un sujet
EP1907015B1 (fr) * 2005-07-14 2012-01-11 Wellstat Biologics Corporation Traitement anticancéreux à l'aide de virus, fluoropyrimidines et camptothécines
EP1917351A4 (fr) * 2005-08-01 2009-12-16 Univ Technologies Int Réovirus atténué
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007059821A1 (fr) * 2005-11-24 2007-05-31 Aicuris Gmbh & Co. Kg Parapoxvirus combines a des agents chimiotherapeutiques cytotoxiques classiques comme biochimiotherapie pour le traitement de cancer
EP2426142A3 (fr) 2006-10-16 2012-06-13 Genelux Corporation Souches de virus de vaccin modifiées pour une utilisation pour le diagnostic et procédé thérapeutique
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008150496A2 (fr) * 2007-05-31 2008-12-11 Genelux Corporation Essai de sensibilité à des agents chimiothérapeutiques
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
WO2009052617A1 (fr) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Régime de traitement pour des troubles prolifératifs
CN102014624A (zh) * 2008-02-08 2011-04-13 帕纳德制药公司 治疗肺癌的吡铂和氨柔比星
WO2009139921A2 (fr) * 2008-05-16 2009-11-19 Genelux Corporation Microorganismes pour la prévention et le traitement de néoplasmes accompagnant une thérapie cellulaire
WO2009143468A1 (fr) * 2008-05-22 2009-11-26 Uti Limited Partnership Prédisposition par suppresseurs de tumeur de cellules hyperproliférantes à une thérapie virale oncolytique
US8470312B2 (en) * 2008-05-27 2013-06-25 Oncolytics Biotech, Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
AU2013204555A1 (en) * 2012-04-30 2013-11-14 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
US11285194B2 (en) 2014-10-24 2022-03-29 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
CN104881181B (zh) * 2015-05-27 2019-07-26 联想(北京)有限公司 显示方法及电子设备
CA3116192A1 (fr) 2018-11-06 2020-05-14 Calidi Biotherapeutics, Inc. Systemes ameliores pour therapie virale oncolytique a mediation cellulaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007322A1 (fr) * 1994-09-06 1996-03-14 La Jolla Cancer Research Foundation Procede de sensibilisation de cellules tumorales a l'aide de l'adenovirus e1a
WO2000050051A2 (fr) * 1999-02-24 2000-08-31 Oncolytics Biotech, Inc. Reovirus pour le traitement de troubles cellulaires proliferants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE178490T1 (de) 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
DE69435118D1 (de) 1993-04-30 2008-08-28 Wellstat Biologics Corp Gereinigte Zusammensetzungen von Newcastle-Krankheitvirus
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
CA2305269C (fr) 1997-10-09 2012-07-03 Pro-Virus, Inc. Traitement de neoplasmes par des virus
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
CA2388807C (fr) * 1999-11-12 2013-08-06 Matthew C. Coffey Virus pour le traitement des troubles de la proliferation cellulaire
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007322A1 (fr) * 1994-09-06 1996-03-14 La Jolla Cancer Research Foundation Procede de sensibilisation de cellules tumorales a l'aide de l'adenovirus e1a
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
WO2000050051A2 (fr) * 1999-02-24 2000-08-31 Oncolytics Biotech, Inc. Reovirus pour le traitement de troubles cellulaires proliferants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. HEISE ET AL.: "Efficacy with a replication-selective Adenovirus plus cisplatin-based chemotherapy: Dependence on sequencing but not p53 functional status or route of administration.", CLINICAL CANCER RESEARCH, vol. 6, December 2000 (2000-12-01), pages 4908 - 4914, XP002235763 *
D. KIRN: "REPLICATION-SELECTIVE ONCOLYTIC ADENOVIRUSES: VIROTHERAPY AIMED AT GENETIC TARGETS IN CANCER", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 19, no. 56, 27 December 2000 (2000-12-27), pages 6660 - 6669, XP008014817, ISSN: 0950-9232 *
TOSHOYOSHI FUJIWARA ET AL: "INDUCTION OF CHEMOSENSITIVITY IN HUMAN LUNG CANER CELLS IN VIVO BY ADENOVIRUS-MEDIATED TRANSFER OF THE WILD-TYPE P53 GENE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, no. 9, 1 May 1994 (1994-05-01), pages 2287 - 2291, XP002025050, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
CA2437468C (fr) 2007-06-19
US20110243890A1 (en) 2011-10-06
EP1361884A2 (fr) 2003-11-19
DK1361884T3 (da) 2011-10-03
AR035227A1 (es) 2004-05-05
WO2002066040A8 (fr) 2003-03-20
ES2367768T3 (es) 2011-11-08
US7608257B2 (en) 2009-10-27
AU2007207860A1 (en) 2007-09-06
CA2437468A1 (fr) 2002-08-29
US20130017172A1 (en) 2013-01-17
US8658158B2 (en) 2014-02-25
US20020168344A1 (en) 2002-11-14
NZ537709A (en) 2006-11-30
NZ527399A (en) 2005-09-30
IL157167A (en) 2014-05-28
ZA200305875B (en) 2004-07-30
US20080031851A1 (en) 2008-02-07
JP2008120837A (ja) 2008-05-29
BR0207691A (pt) 2006-01-31
AU2007207860B2 (en) 2008-10-23
JP2012072192A (ja) 2012-04-12
JP2004517966A (ja) 2004-06-17
EP2314301A2 (fr) 2011-04-27
US20100021432A1 (en) 2010-01-28
IL157167A0 (en) 2004-02-08
US7264798B2 (en) 2007-09-04
US7964187B2 (en) 2011-06-21
MXPA03007486A (es) 2003-12-08
JP4951194B2 (ja) 2012-06-13
EP2314301A3 (fr) 2011-08-17
EP1361884B1 (fr) 2011-07-20
ATE516807T1 (de) 2011-08-15
AU2002234453B2 (en) 2007-05-17
WO2002066040A2 (fr) 2002-08-29
HK1060520A1 (en) 2004-08-13

Similar Documents

Publication Publication Date Title
WO2002066040A8 (fr) Sensibilisation des cellules neoplasiques resistant aux agents chimiotherapeutiques avec un reovirus
EP1363625A4 (fr) Combinaisons de medicaments (p. ex. un benzimidazole et pentamidine) dans le traitement de troubles neoplasiques
PT1339399E (pt) Combinacoes de drogas (e.g., clorpromazina e pentamidina) para o tratamento de desordens neoplasicas
EA200400774A1 (ru) Лечение атрофии мышц с помощью селективных модуляторов андрогенового рецептора
WO2004089416A3 (fr) Polytherapie utilisant un inhibiteur de type 1 de la 11beta-hydroxysteroide deshydrogenase et un agent hypotenseur dans le traitement du syndrome metabolique et des troubles et maladies associes
TW200505509A (en) Tamper resistant transdermal dosage form
WO2004009776A3 (fr) Traitement de troubles en relation avec le tnf$g(a)
NO20034996D0 (no) Nye arylsusfonamidforbindelser for behandlingen av fedme, type II diabetesog CNS-forstyrrelser
WO2002036123A3 (fr) Nouveaux traitements destines au syndrome des jambes sans repos
MXPA03000873A (es) Derivados de quinazolina, medicamentos que contienen estos compuestos, su uso y metodos para la produccion de los mismos.
EP1406122A3 (fr) Composition photosensible et générateur d'acide
TR200200821T2 (tr) 5-Beta-sapojenin ve pseudosapojenin türevleri ve bunların bunama tedavisinde kullanımı.
NO20033821D0 (no) Anvendelse av GABA A inverse agonister i kombinasjon med nikotinreseptordelagonister, östrogen, selektive östrogenmodulatorer, ellervitamin E for behandling av kognitive forstyrrelser
HK1057864A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders.
EP1698945A4 (fr) Support a revetement de resine pour agent revelateur electrophotographique, son procede de fabrication et agent revelateur electrophotographique mettant en application ce support
WO2004026226A8 (fr) Composes, compositions et procedes
WO2004082631A3 (fr) Methodes de preparation et d'utilisation de 1$g(a),24(s)-dihydroxyvitamine d2
AU1700700A (en) Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
Albert Fever therapy for general paresis.
WO2004016599A8 (fr) Procede de preparation de melamine
AU2001268081A1 (en) Developing methods for photoresist, apparatuses for coating
ZA200405173B (en) 2'-halo-3',5'-dialkoxyphen-1'yl-imino-2-imidazoline derivatives and the use thereof for the treatment of urinary incontinence.
WO2002088714A3 (fr) Personnalisation d'une therapie a l'aide d'agents antineoplasiques
DK1459748T3 (da) (S,S)-reboxetin til behandling af perifer neuropati
WO2004061082A3 (fr) Mutations du gene fanc dans le cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: 157167

Country of ref document: IL

Ref document number: 2003/05875

Country of ref document: ZA

Ref document number: 200305875

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2437468

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 527399

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002565598

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007486

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002701122

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002234453

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002701122

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 527399

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 527399

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: PI0207691

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2002234453

Country of ref document: AU